Skip to main content

Advertisement

SpringerLink
Log in

Immunosuppression in Pancreas Transplantation: What Has Changed in 20 Years?

  • Pancreas Transplantation (DA Axelrod, Section Editor)
  • Published:
Current Transplantation Reports Aims and scope Submit manuscript

Abstract

Pancreas transplantation offers a functional cure for many patients suffering from diabetes mellitus. Although the outcomes of pancreas transplants were originally plagued with high rates of acute cellular rejection, innovations in immunosuppression regimens over the last two decades have helped steadily improve the graft survival of pancreas transplants. This review surveys the latest trends in immunosuppressive management for pancreas transplant recipients, discussing the controversies and weighing the evidence supporting induction therapy, steroid avoidance/withdrawal, mTOR inhibitors, and new regimens based on costimulatory blockade agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kandaswamy R, Skeans MA, Gustafson SK, et al. Pancreas. Am J Transplant. 2016;16 Suppl 2:47–68. This latest report from the Scientific Registry of Transplant Recipients captures many of the important trends in changing immunosuppression management for pancreas transplants over the past decade.

    Article  PubMed  Google Scholar 

  2. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2011;8:6–16.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Israni AK, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2012 Annual Data Report: pancreas. Am J Transplant. 2014;14 Suppl 1:45–68.

    Article  PubMed  Google Scholar 

  4. Niederhaus SV, Kaufman DB, Odorico JS. Induction therapy in pancreas transplantation. Transpl Int. 2013;26:704–14.

    Article  CAS  PubMed  Google Scholar 

  5. Stratta RJ, Alloway RR, Hodge E, et al. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant. 2002;16:60–8.

    Article  PubMed  Google Scholar 

  6. Stratta RJ, Alloway RR, Lo A, et al. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant Proc. 2005;37:3531–4.

    Article  CAS  PubMed  Google Scholar 

  7. Kaufman DB, Iii GW, Bruce DS, et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant. 2003;3:855–64.

    Article  PubMed  Google Scholar 

  8. Lo A, Stratta RJ, Alloway RR, et al. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transpl Int. 2001;14:396–404.

    Article  CAS  PubMed  Google Scholar 

  9. Desai DM, Scandling JD, Knoppel C, et al. Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation. Transplant Proc. 1998;30:1552–4.

    Article  CAS  PubMed  Google Scholar 

  10. Cantarovich D, Karam G, Giral-Classe M, et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int. 1998;54:1351–6.

    Article  CAS  PubMed  Google Scholar 

  11. Zachariah M, Gregg A, Schold J, et al. Alemtuzumab induction in simultaneous pancreas and kidney transplantation. Clin Transplant. 2013;27:693–700. This analysis of registry data of simultaneous pancreas-kidney transplant recipients shows no benefit in graft survival or overall patient survival in recipients treated with basiliximab, alemtuzumab or thymoglobulin induction compared to recipients receiving no induction.

    CAS  PubMed  Google Scholar 

  12. Bazerbachi F, Selzner M, Boehnert MU, et al. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation. 2011;92:1039–43.

    CAS  PubMed  Google Scholar 

  13. Magliocca JF, Odorico JS, Pirsch JD, et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am J Transplant. 2008;8:1702–10.

    Article  CAS  PubMed  Google Scholar 

  14. Pascual J, Pirsch JD, Odorico JS, et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation. 2009;87:125–32.

    Article  CAS  PubMed  Google Scholar 

  15. Stratta RJ, Rogers J, Orlando G, et al. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin. Expert Opin Biol Ther. 2014;14:1723–30. In this prospective randomized trial, recipients of simultaneous pancreas-kidney transplants received either alemtuzumab or thymoglobulin induction immunosuppression. There were no significant differences in 5 year patient, pancreatic graft or renal graft survival, although there was a trend for improved acute rejection and lower rates of major infection with alemtuzumab.

    Article  CAS  PubMed  Google Scholar 

  16. Farney A, Sundberg A, Moore P, et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant. 2008;22:41–9.

    PubMed  Google Scholar 

  17. Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation. 2009;88:810–9.

    Article  CAS  PubMed  Google Scholar 

  18. Bosmuller C, Ollinger R, Sieb M, et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. Ann Transplant. 2012;17:45–51.

    PubMed  Google Scholar 

  19. Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction—long-term results. Am J Transplant. 2006;6:331–9.

    Article  CAS  PubMed  Google Scholar 

  20. Vendrame F, Hopfner YY, Diamantopoulos S, et al. Risk factors for type 1 diabetes recurrence in immunosuppressed recipients of simultaneous pancreas-kidney transplants. Am J Transplant. 2015. Lack of induction immunosuppression was one of the risk factors associated with recurrent type 1 diabetes in recipients of simultaneous pancreas-kidney transplants.

  21. Rangel EB. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Expert Opin Drug Metab Toxicol. 2012;8:1531–48.

    Article  CAS  PubMed  Google Scholar 

  22. Aoun M, Eschewege P, Hamoudi Y, et al. Very early steroid withdrawal in simultaneous pancreas-kidney transplants. Nephrol Dial Transplant. 2007;22:899–905.

    Article  CAS  PubMed  Google Scholar 

  23. Fridell JA, Agarwal A, Powelson JA, et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. Transplantation. 2006;82:389–92.

    Article  CAS  PubMed  Google Scholar 

  24. Jordan ML, Chakrabarti P, Luke P, et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation. 2000;69:265–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kahl A, Bechstein WO, Lorenz F, et al. Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil. Transplant Proc. 2001;33:1694–5.

    Article  CAS  PubMed  Google Scholar 

  26. Knight RJ, Kerman RH, McKissick E, et al. A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Transplant Proc. 2005;37:3538–41.

    Article  CAS  PubMed  Google Scholar 

  27. Knight RJ, Podder H, Kerman RH, et al. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Transplantation. 2010;89:727–32.

    Article  CAS  PubMed  Google Scholar 

  28. Luzi L, Picena Sereni L, Battezzati A, et al. Metabolic effects of a corticosteroid-free immunosuppressive regimen in recipients of pancreatic transplant. Transplantation. 2003;75:2018–23.

    Article  CAS  PubMed  Google Scholar 

  29. Malheiro J, Martins L, Fonseca I, et al. Steroid withdrawal in simultaneous pancreas-kidney transplantation: a 7-year report. Transplant Proc. 2009;41:909–12.

    Article  CAS  PubMed  Google Scholar 

  30. Rajab A, Pelletier RP, Ferguson RM, et al. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients. Transplantation. 2007;84:1131–7.

    Article  CAS  PubMed  Google Scholar 

  31. Reddy KS, Devarapalli Y, Mazur M, et al. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Transplant Proc. 2010;42:2006–8.

    Article  CAS  PubMed  Google Scholar 

  32. Sundberg AK, Roskopf JA, Hartmann EL, et al. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. Transplant Proc. 2005;37:1294–6.

    Article  CAS  PubMed  Google Scholar 

  33. Tanchanco R, Krishnamurthi V, Winans C, et al. Beneficial outcomes of a steroid-free regimen with thymoglobulin induction in pancreas-kidney transplantation. Transplant Proc. 2008;40:1551–4.

    Article  CAS  PubMed  Google Scholar 

  34. Uemura T, Ramprasad V, Matsushima K, et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. Transplantation. 2011;92:678–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Vessal G, Wiland AM, Philosophe B, et al. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. Clin Transplant. 2007;21:491–7.

    Article  PubMed  Google Scholar 

  36. Amodu LI, Tiwari M, Levy A, et al. Steroid maintenance is associated with an increased risk of infections but has no effect on patient and graft survival in pancreas transplantation: A retrospective review of the UNOS database. Pancreatology. 2015;15:554–62. In this retrospective analysis of UNOS database data on pancreas and kidney-pancreas transplant recipients, the use of maintenance steroids increased the risk of infectious complications but did not decrease the rate of patient death or graft loss.

    Article  PubMed  Google Scholar 

  37. Montero N, Webster AC, Royuela A, et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev. 2014;9, CD007669. This Cochrane Database review found no compelling evidence in the literature to recommend use of steroids in pancreas transplant recipients.

    PubMed  Google Scholar 

  38. Cantarovich D, Karam G, Hourmant M, et al. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation. Am J Transplant. 2005;5:1332–8.

    Article  CAS  PubMed  Google Scholar 

  39. Gruessner RW, Sutherland DE, Parr E, et al. A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplant Proc. 2001;33:1663–4.

    Article  CAS  PubMed  Google Scholar 

  40. Kandaswamy R, Khwaja K, Gruessner AC, et al. A prospective, randomized trial of steroid-free maintenance vs. delayed steroid withdrawal, using a sirolimus/tacrolimus regimen in simultaneous pancreas-kidney transplants (SPK) [abstract no: 1474]. Am J Transplant. 2003;3:1.

    Article  Google Scholar 

  41. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet. 2000;355:376–7.

    Article  CAS  PubMed  Google Scholar 

  42. Gallon LG, Winoto J, Chhabra D, et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation. 2007;83:1324–9.

    Article  CAS  PubMed  Google Scholar 

  43. Freise CE, Kang SM, Feng S, et al. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. Arch Surg. 2003;138:1121–5. discussion 1125–1126.

    Article  PubMed  Google Scholar 

  44. Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation. 2002;73:169–77.

    Article  CAS  PubMed  Google Scholar 

  45. di Francesco F, Cautero N, Vincenzi P, et al. One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation. Transplantation. 2008;86:1146–7.

    Article  PubMed  Google Scholar 

  46. Rangel EB. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2014;10:1585–605.

    Article  CAS  PubMed  Google Scholar 

  47. Laham G, Sleiman S, Soler Pujol G, et al. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients. Transplant Proc. 2010;42:309–13.

    Article  CAS  PubMed  Google Scholar 

  48. Gautam A, Morrissey PE, Gohh R, et al. Experience with sirolimus for calcineurin minimization/elimination in pancreas-after-kidney transplantation. Transplant Proc. 2005;37:3542–3.

    Article  CAS  PubMed  Google Scholar 

  49. Matias P, Araujo MR, Romao Jr JE, et al. Conversion to sirolimus in kidney-pancreas and pancreas transplantation. Transplant Proc. 2008;40:3601–5.

    Article  CAS  PubMed  Google Scholar 

  50. Girman P, Lipar K, Koznarova R, et al. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. Transplant Proc. 2010;42:1999–2002.

    Article  CAS  PubMed  Google Scholar 

  51. Kandula P, Fridell J, Taber TE, et al. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. Transplantation. 2012;94:940–6.

    Article  CAS  PubMed  Google Scholar 

  52. Ciancio G, Sageshima J, Chen L, et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. Am J Transplant. 2012;12:3363–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Sageshima J, Ciancio G, Chen L, et al. Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation. Clin Transplant. 2014;28:797–801. This non-randomized retrospective case series shows good outcomes can be obtained using combined maintenance everolimus and low-dose tacrolimus in a mycophenolate mofetil-sparing regimen.

    Article  CAS  PubMed  Google Scholar 

  54. Porubsky M, Gruessner AC, Rana A, et al. Excellent outcomes can be achieved in young pancreas transplant alone recipients by addition of sirolimus to maintenance immunosuppression regimen. Transplant Proc. 2014;46:1932–5.

    Article  CAS  PubMed  Google Scholar 

  55. Chatzizacharias NA, Vaidya A, Sinha S, et al. Risk analysis for deterioration of renal function after pancreas alone transplant. Clin Transplant. 2012;26:387–92.

    Article  PubMed  Google Scholar 

  56. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443–53.

    Article  CAS  PubMed  Google Scholar 

  57. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535–46.

    Article  CAS  PubMed  Google Scholar 

  58. Mujtaba MA, Sharfuddin AA, Taber T, et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. Am J Transplant. 2014;14:2657–61. The successful conversion of a kidney-pancreas transplant recipient suffering calcineurin inhibitor-toxicity to a tacrolimus-sparing immunosuppression regimen based on belatacept is described.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emory Transplant Center, 101 Woodruff Circle, WMRB 5105, Atlanta, GA, 30322, USA

    William H. Kitchens & Nicole A. Turgeon

Authors
  1. William H. Kitchens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole A. Turgeon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicole A. Turgeon.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pancreas Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kitchens, W.H., Turgeon, N.A. Immunosuppression in Pancreas Transplantation: What Has Changed in 20 Years?. Curr Transpl Rep 3, 154–160 (2016). https://doi.org/10.1007/s40472-016-0098-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40472-016-0098-5

Keywords

Search

Navigation